open access
Interstitial pneumonia connected with rituximab therapy — case report
open access
Abstract
Rituximab (RTX) is a monoclonal antibody against the CD20 antigen found on the surface of B cells. RTX causes cell lysis and is therefore used to treat lymphomas, leukaemias, transplant rejection and certain autoimmune disorders. Pulmonary adverse events associated with RTX have been reported in literature. We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Symptoms and radiological changes resolved with prednisone therapy.
Abstract
Rituximab (RTX) is a monoclonal antibody against the CD20 antigen found on the surface of B cells. RTX causes cell lysis and is therefore used to treat lymphomas, leukaemias, transplant rejection and certain autoimmune disorders. Pulmonary adverse events associated with RTX have been reported in literature. We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Symptoms and radiological changes resolved with prednisone therapy.
Keywords
interstitial pneumonia, adverse effects, monoclonal antibodies, rituximab
About this articleTitle
Interstitial pneumonia connected with rituximab therapy — case report
Journal
Advances in Respiratory Medicine
Issue
Pages
453-459
Bibliographic record
Pneumonol Alergol Pol 2013;81(5):453-459.
Keywords
interstitial pneumonia
adverse effects
monoclonal antibodies
rituximab
Authors
Dorota Wyrostkiewicz
Wojciech Skorupa
Inga Barańska
Jan Kuś
